By Jamie Lennox ( November 10, 2026, 6:17 PM GMT) -- Boehringer has asked a London court to stop Teva launching its generic version of diabetes drug empagliflozin, arguing that the Israeli drugmaker is set to infringe extended patent protections covering the treatment in the U.K....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.